105604-45-3

Upstream product

• 67-56-1 methanol 
• 105604-42-0 methyl 11α,15(S)-bis<<(1,1-dimethylethyl)diphenylsilyl>oxy>-6,9α-epoxyprosta-5(Z),13(E)-dien-1-oate 
• 105662-10-0 (R)-5-{(2R,3aR,4R,5R,6aS)-5-(tert-Butyl-diphenyl-silanyloxy)-4-[(E)-(S)-3-(tert-butyl-diphenyl-silanyloxy)-oct-1-enyl]-2-methoxy-hexahydro-cyclopenta[b]furan-2-yl}-5-fluoro-pentanoic acid methyl ester 
• 33854-16-9 (+)-prostaglandin F_2α 
• 107097-94-9 methyl 11α,15(S)-bis<<(1,1-dimethylethyl)diphenylsilyl>oxy>-6,9α-epoxy-6-methoxyprost-13(E)-en-1-oate 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 105604-43-1 Methyl 11α,15S-bis[[(1,1-dimethylethyl)-diphenylsilyl]oxy]-6,9α-epoxy-5S-fluoro-6S-methoxyprost-13E-en-1-oate 
• 107082-06-4 (S)-5-{(2R,3aR,4R,5R,6aS)-5-(tert-Butyl-diphenyl-silanyloxy)-4-[(E)-(S)-3-(tert-butyl-diphenyl-silanyloxy)-oct-1-enyl]-2-methoxy-hexahydro-cyclopenta[b]furan-2-yl}-5-fluoro-pentanoic acid methyl ester 
• 105662-11-1 methyl 11α,15(S)-bis<<(1,1-dimethylethyl)diphenylsilyl>oxy>-6,9α-epoxy-5(S)-fluoroprosta-6,13(E)-dien-1-oate 

Downstream Products

• 105662-10-0 (R)-5-{(2R,3aR,4R,5R,6aS)-5-(tert-Butyl-diphenyl-silanyloxy)-4-[(E)-(S)-3-(tert-butyl-diphenyl-silanyloxy)-oct-1-enyl]-2-methoxy-hexahydro-cyclopenta[b]furan-2-yl}-5-fluoro-pentanoic acid methyl ester 
• 105604-44-2 (R)-5-{(2S,3aR,4R,5R,6aS)-5-(tert-Butyl-diphenyl-silanyloxy)-4-[(E)-(S)-3-(tert-butyl-diphenyl-silanyloxy)-oct-1-enyl]-2-methoxy-hexahydro-cyclopenta[b]furan-2-yl}-5-fluoro-pentanoic acid methyl ester 
• 105638-44-6 methyl 11α,15(S)-bis<<(1,1-dimethylethyl)diphenylsilyl>oxy>-6,9α-epoxy-5-fluoroprosta-5(E),13(E)-dien-1-oate 

Relevant academic research and scientific papers

Synthesis of 5-Fluoroprostacyclin

Protected prostacyclin derivatives were reacted with perchloryl fluoride in methanol.The resultant 5-fluoro-6-methoxy derivatives were separated and identified.Pyrolysis of the individual isomers in the presence of magnesium triflate led to 5(R)- or 5(S)-

Method for preparing 5-fluoroprostacyclins

This invention relates to a process for preparing 5-fluoroprostacyclins that are useful for the treatment of platelet dysfunction.